Waterfront Wealth Inc. Boosts Stock Holdings in Sanofi (NASDAQ:SNY)

Waterfront Wealth Inc. grew its position in shares of Sanofi (NASDAQ:SNY) by 46.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,958 shares of the company’s stock after acquiring an additional 15,748 shares during the quarter. Waterfront Wealth Inc.’s holdings in Sanofi were worth $2,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. boosted its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the last quarter. Concord Wealth Partners boosted its holdings in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in shares of Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after buying an additional 313 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on SNY. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Trading Up 1.0 %

Shares of SNY opened at $54.13 on Friday. The business’s 50-day moving average price is $50.79 and its 200-day moving average price is $52.50. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a market cap of $137.37 billion, a PE ratio of 21.74, a P/E/G ratio of 1.00 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.